Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Clinical Study of Apatinib Mesylate in Combination With a Physician's Choice Regimen for Her-2 Negative, HR-positive Progressive Breast Cancer.

NCT06339281 is registered in ClinicalTrials.gov with Li Huiping as lead sponsor.

NCT NCT06339281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06339281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Clinical Study of Apatinib Mesylate in Combination With a Physician's Choice Regimen for Her-2 Negative, HR-positive Progressive Breast Cancer.
Lead sponsor
Li Huiping
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 1, 2024
Completion date
December 31, 2026
Enrollment
68 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer